Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02893332

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:50.225598+00:00

Published At

2021-02-03T00:00:00+00:00

Record Updated At

2021-02-03

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Stage IV EGFR Mutated Non-Small Cell Lung Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2021-02-03"

protocolSection.identificationModule.nctId

"NCT02893332"

protocolSection.identificationModule.officialTitle

"Tyrosine-kinase Inhibitor \uff08TKI\uff09 With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Stage IV EGFR Mutated Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.